NCT07828938Not yet recruiting
Short- and Mid-term Therapeutic, Prognostic, and Societal Impact of Implementing Intraoperative Assessment of Pulmonary Resection Quality for Lung Cancer
Source: ClinicalTrials.gov · Last updated 18 Sept 2026
Brief summary (registry, in English)
QUALITYSURG is a multicenter interventional study evaluating whether a collaborative intraoperative quality checklist (QualitySurg List) can improve the oncological quality of lung cancer resections. The study includes three phases: a Delphi consensus to define checklist contents, a cluster-randomized trial comparing checklist use versus standard care, and a prospective implementation phase assessing long-term adoption. The primary endpoint is the proportion of confirmed R0 resections according to 2020 IASLC criteria.Two optional ancillary studies are embedded within the main protocol. BIO-QualitySurg aims to evaluate biological markers of residual disease and develop the concept of a biological R0 resection using circulating tumor DNA (ctDNA), tissue biomarkers, and integrated molecular analyses. BIO-QualitySurg is complementary to the objectives of the European REALCARE project, which investigates ctDNA-based approaches for residual disease assessment and personalized cancer management. VIDEO-QualitySurg contributes to the broader objective of improving quality assessment and standardization of thoracic oncologic surgery through digital technologies and artificial intelligence.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 2400 (estimated)
- First submitted
- 7 Sept 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 1 Sept 2029
- Lead sponsor
- Fondation Hôpital Saint-Joseph
- Diseases
- Lung cancer
- NCT number
- NCT07828938
What you commit to
- Study type: Interventional
- Planned participants: 2400
- From 1 Sept 2026 to the primary completion date, 1 Sept 2029
- 20 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of HIV infection, allogeneic stem cell or solid organ transplant
- History of any hematological disease that is not considered to be in complete remission
Age
- History of cancer less than five years old excluding non-melanocytic skin cancer prior to enrollment
Other
- Pure ground glass opacities regardless of tumor size
- iterative re-interventions of the same stay (keep only the first planned intervention for the main analysis)
- Patients under guardianship or conservatorship
- Patients deprived of their liberty or under judicial protection
- Pregnant women
Who the study is looking for
- Age ≥18 years
- Have solid NSCLC clinical stage IA-IIIA (according to the 9th edition of the TNM) and be eligible for surgical resection.
- Have a respiratory function and a state of performance (ECOG) allowing the surgical procedure.
- Primary intervention for NSCLC, whether isolated or included in a multimodal regimen (neoadjuvant/adjuvant).
- Intervention can be performed by minimally invasive surgery (VATS, RATS) or by thoracotomy.
- Have given written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (20)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.